Additionally, studies are examining novel PD-L1-targeting drugs like INCB099318 (NCT04272034) and anti-PD-L1 monoclonal antibody injections (LDP) (NCT04718584) for efficacy and safety in advanced penile carcinoma. This evidence concerns the gene CD274 and penile carcinoma.